ArticleFrontiers in cardiovascular medicine2025
Eligible patients with heart failure prescribed vs. not prescribed vericiguat in the United States.
Article in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: This study compared characteristics of patients with heart failure (HF) prescribed vericiguat vs. eligible patients with HF not prescribed vericiguat, and sought to identify factors associated with vericiguat use in real-world settings. Methods: We analysed 2022-2023 Adelphi HF cross-sectional survey from United States physicians and their adult patients. Patients prescribed vericiguat were compared with patients eligible for but not prescribed vericiguat. Vericiguat eligibility was defined as ≥1 prior HF hospitalization at any time, ejection fraction (EF) <45%, and no stage 5 chronic kidney disease or need for dialysis. Both cohorts were compared descriptively, and logistic regression used to identify factors associated with vericiguat non-use. Results: Overall, 93 physicians reported data on 228 patients with HF (mean age [SD]: 66.8 years [11.8], 65.7% male, 60.1% White), with 98 patients prescribed vericiguat and 130 patients eligible but not prescribed vericiguat. Patients eligible but not prescribed vericiguat had more comorbid hypertension (62.3% vs. 45.9%), hyperlipidemia (52.3% vs. 34.7%), and lower EF (mean [SD]: 34.7% [5.8%] vs. 41.7% [9.6%]), all Conclusion: Among patients with HF in contemporary US clinical practice, patients prescribed vericiguat have distinct demographic and clinical profiles compared to eligible patients not prescribed vericiguat. Future research should confirm these findings and explore whether subgroups of eligible patients less likely to be prescribed vericiguat may benefit from targeted implementation initiatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.